PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of liphdisBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleLipids in Health and DiseaseJournal Front Page
 
From:
Published online 2010 July 15. doi: 10.1186/1476-511X-9-72

Table 3

Blood catecholamine data for healthy adults consuming Capsimax™ and placebo in a randomized cross-over design

VariablePre2 hr
(pre-ex)
2.5 hr
(1 min post ex)
4 hr
(90 min post ex)
Epinephrine (pg·mL-1)
Capsimax™
41.54 ± 33.5640.09 ± 29.8369.34 ± 43.75 *45.36 ± 39.36
Epinephrine (pg·mL-1)
Placebo
37.65 ± 27.1636.54 ± 21.3165.08 ± 51.10 *34.49 ± 22.12
Norepinephrine (pg·mL-1)
Capsimax™
264.90 ± 132.66378.63 ± 210.31**491.08 ± 211.54**440.10 ± 220.34 **
Norepinephrine (pg·mL-1)
Placebo
242.03 ± 157.63326.84 ± 185.89**553.53 ± 200.58**344.61 ± 210.45**

Data are Mean ± SD

No interaction or condition effects were noted for EPI or NE (p > 0.05).

* A time effect was noted for EPI (p < 0.0001); values higher than Pre at 2.5 hr.

** A time effect was noted for NE (p < 0.0001); values higher than Pre at 2 hr, 2.5 hr, and 4 hr.